GeneDx Holdings Corp Ordinary Shares - Class A WGS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
-
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
-
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
-
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit
-
Rosen Law Firm Urges GeneDx Holdings Corp. (NASDAQ: WGS) Stockholders to Contact the Firm for Information About Their Rights
-
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
-
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - Hagens Berman
-
Investor Notice: Robbins LLP Informs Investors of the GeneDx Holdings Corp. Class Action Lawsuit
Trading Information
- Previous Close Price
- $52.21
- Day Range
- $51.51–53.70
- 52-Week Range
- $32.21–170.87
- Bid/Ask
- $53.50 / $54.34
- Shares Outstanding
- 29.69M
- Market Cap
- $1.54B
- Volume/Avg
- 795,921 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 37.94
- Price/Sales
- 3.38
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,300
- Website
- https://www.genedx.com
Valuation
|
Metric
|
WGS
|
|---|---|
Price/Earnings (Normalized) | 37.94 |
Price/Book Value | 6.04 |
Price/Sales | 3.38 |
Price/Cash Flow | 45.65 |
Price/Earnings
WGS
Financial Strength
|
Metric
|
WGS
|
|---|---|
Quick Ratio | 2.83 |
Current Ratio | 3.09 |
Interest Coverage | −28.62 |
Quick Ratio
WGS
Profitability
|
Metric
|
WGS
|
|---|---|
Return on Assets (Normalized) | 5.32% |
Return on Equity (Normalized) | 9.32% |
Return on Invested Capital (Normalized) | 6.94% |
Return on Assets
WGS
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Yhlywtwlny | Pvsfq | $175B | |||
| Danaher Corp
DHR
| Qsyrjrdmtm | Xgxnx | $130B | |||
| IDEXX Laboratories Inc
IDXX
| Lmcxhyylb | Ppzll | $44B | |||
| Agilent Technologies Inc
A
| Gddtmhmxw | Dsqqc | $37B | |||
| Waters Corp
WAT
| Cbzbfcz | Hlvj | $36B | |||
| IQVIA Holdings Inc
IQV
| Trsmlqjb | Tmqby | $31B | |||
| Illumina Inc
ILMN
| Jbrmhwfr | Ntqhhf | $24B | |||
| Mettler-Toledo International Inc
MTD
| Mfpslnpnyb | Xmtwjz | $23B | |||
| Quest Diagnostics Inc
DGX
| Gbxjynhly | Vrydv | $22B | |||
| Labcorp Holdings Inc
LH
| Bfmmkcgn | Lzxcb | $21B |
United States